North Carolina Headlines

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Cystinosis Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Cystinosis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Cystinosis Market

• The market size for Cystinosis in the leading markets is expected to grow significantly by 2036.

• The United States accounted for the highest Cystinosis treatment market size in the 7MM in 2025, compared with the EU4 countries, the United Kingdom, and Japan.

• According to DelveInsight’s estimates, the Cystinosis market in the 7MM was approximately USD 260 million in 2025 and is expected to increase substantially by 2036.

• In 2025, the United States accounted for approximately USD 225 million, representing the largest share of the Cystinosis market among the seven major markets.

• The report estimates that nearly 1,600 diagnosed prevalent cases of Cystinosis were reported across the 7MM in 2025, with the patient population projected to increase through 2036.

• In the United States, there were more than 750 diagnosed prevalent cases of Cystinosis in 2025, representing the largest diagnosed patient population among the seven major markets.

• Among the disease subtypes, Infantile Nephropathic Cystinosis represented approximately 94% of diagnosed cases in 2025, making it the most common clinical presentation of the disease.

• More than 750 patients were diagnosed with Cystinosis across EU4 and the United Kingdom in 2025, while Japan accounted for more than 45 diagnosed prevalent cases during the same period.

• Leading Cystinosis companies, such as Thiogenesis Therapeutics, Novartis, Amgen, Chiesi Farmaceutici, Viatris, Leadiant Biosciences, Recordati Rare Diseases, and others, are developing innovative therapies that are expected to reshape the Cystinosis treatment landscape over the coming years.

• The promising Cystinosis therapies in clinical development include TTI-0102 (L606), DFT383 (AVR-RD-04), BRH101, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/cystinosis-market

Key Factors Driving the Cystinosis Market

• Increasing Disease Awareness and Earlier Diagnosis: Improvements in genetic testing, increased physician awareness, and advances in newborn and metabolic screening are enabling earlier diagnosis of Cystinosis. Early identification allows timely initiation of cysteamine therapy, improving long-term renal and systemic outcomes while increasing the number of treated patients.

• Growing Adoption of Cysteamine-based Therapies: Current disease management is centered on cysteamine therapy, including systemic treatments such as PROCYSBI and CYSTAGON/Nicystagon, along with ophthalmic therapies including CYSTARAN and CYSTADROPS. These therapies have significantly improved survival and transformed Cystinosis from a fatal pediatric disease into a chronic condition requiring lifelong management.

• Advancement of Disease-modifying Therapies: Several companies are developing next-generation cysteamine formulations and gene therapies designed to improve treatment adherence, reduce dosing frequency, address extra-renal complications, and potentially correct the underlying genetic defect responsible for Cystinosis.

Cystinosis Competitive Landscape

Several Cystinosis therapies are currently under clinical development, including TTI-0102 (Thiogenesis Therapeutics), DFT383 (Novartis), BRH101 (Birch Therapeutics), and LB202 (Leadiant Biosciences).

These investigational therapies utilize diverse approaches, including optimized cysteamine prodrugs, gene replacement therapy targeting the CTNS gene, and novel drug delivery systems designed to improve cystine depletion while reducing treatment burden. These next-generation therapies have the potential to improve patient adherence, delay disease progression, and address long-standing unmet needs associated with lifelong cysteamine therapy.

Discover more about therapies set to grab major Cystinosis market share @ Cystinosis Treatment Landscape

Recent Developments in the Cystinosis Market

• In November 2025, Thiogenesis Therapeutics announced plans for a pivotal Phase III trial of TTI-0102 in nephropathic Cystinosis, with an Investigational New Drug (IND) application expected to be submitted during the second half of 2026. Cystinosis – Market Insights, Epidemiology, and Market Forecast – 2036_Sample Pages_27_January_2026.pptx

• In November 2025, Thiogenesis also reported positive interim Phase II data supporting the continued development of TTI-0102, demonstrating encouraging pharmacokinetic and biomarker results. Cystinosis – Market Insights, Epidemiology, and Market Forecast – 2036_Sample Pages_27_January_2026.pptx

• In April 2025, the European Medicines Agency (EMA) expanded the indication of CYSTADROPS to include infants aged six months and older following a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP). Cystinosis – Market Insights, Epidemiology, and Market Forecast – 2036_Sample Pages_27_January_2026.pptx

• In March 2024, CYSTADROPS was launched in Japan by Viatris under an exclusive licensing agreement with Recordati Rare Diseases, becoming the first approved treatment in Japan demonstrated to reduce corneal cystine crystal deposits. Cystinosis – Market Insights, Epidemiology, and Market Forecast – 2036_Sample Pages_27_January_2026.pptx

• In July 2021, the US FDA granted Fast Track Designation to AVR-RD-04 (now DFT383) for the treatment of Cystinosis. Cystinosis – Market Insights, Epidemiology, and Market Forecast – 2036_Sample Pages_27_January_2026.pptx

What is Cystinosis?

Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by pathogenic mutations in the CTNS gene, resulting in defective lysosomal cystine transport and progressive accumulation of cystine crystals throughout the body. The disease primarily affects the kidneys during infancy but gradually involves multiple organs, including the eyes, muscles, thyroid, pancreas, and central nervous system. Without appropriate treatment, Cystinosis leads to progressive renal failure and multiple systemic complications. Current management relies on lifelong cysteamine therapy to reduce intracellular cystine accumulation and delay disease progression, while emerging gene therapies and next-generation cysteamine formulations aim to provide more durable disease control and improve patients’ quality of life.

Cystinosis Epidemiology Segmentation

The Cystinosis epidemiology section provides insights into the historical and current Cystinosis patient pool and forecasted trends for the leading markets. The Cystinosis market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of Cystinosis

• Total Diagnosed Prevalent Cases of Cystinosis

• Type-specific Diagnosed Prevalent Cases of Cystinosis

• Treated Cases of Cystinosis

Scope of the Cystinosis Market Report

• Therapeutic Assessment: Cystinosis current marketed and emerging therapies

• Cystinosis Market Dynamics: Key Market Forecast Assumptions of Emerging Cystinosis Drugs and Market Outlook

• Key Companies: Thiogenesis Therapeutics, Novartis, Amgen, Chiesi Farmaceutici, Viatris, Recordati Rare Diseases, Leadiant Biosciences, Birch Therapeutics, and others

• Key Therapies: TTI-0102 (L606), DFT383 (AVR-RD-04), PROCYSBI, CYSTAGON/Nicystagon, CYSTARAN, CYSTADROPS, BRH101, LB202, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, Cystinosis Market Access and Reimbursement

To know more about Cystinosis companies working in the treatment market, visit @ Cystinosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cystinosis Market Report Introduction

2. Executive Summary for Cystinosis

3. SWOT Analysis of Cystinosis

4. Cystinosis Patient Share (%) Overview at a Glance

5. Cystinosis Market Overview at a Glance

6. Cystinosis Background and Overview

7. Cystinosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Cystinosis

9. Cystinosis Current Treatment and Medical Practices

10. Cystinosis Unmet Needs

11. Cystinosis Emerging Therapies

12. Cystinosis Market Outlook

13. Country-Wise Cystinosis Market Analysis (2022–2036)

14. Cystinosis Market Access and Reimbursement of Therapies

15. Cystinosis Market Drivers

16. Cystinosis Market Barriers

17. Cystinosis Appendix

18. Cystinosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/